Advertisement
BIO vs DHR
Which Stock Would AI Choose? Bio-Rad Laboratories (BIO) vs. Danaher (DHR) Stock Comparison
Key Takeaways
- Bio-Rad Laboratories (BIO) and Danaher (DHR) both operate in the life sciences and diagnostics space, offering investors exposure to healthcare tools and bioprocessing markets.
- Recent market activity shows DHR experiencing notable pressure with shares trading below key moving averages and posting double-digit year-to-date declines amid broader sector weakness.
- BIO has shown relative resilience supported by new product launches and investor interest, maintaining a higher share price level compared to its recent trading range.
- Both companies face similar sector headwinds including variable demand in diagnostics and life science research, yet differ in scale and acquisition-driven growth strategies.
- Market sentiment reflects caution for DHR due to valuation compression, while BIO benefits from targeted innovation updates in recent weeks.
- Relative performance highlights trade-offs between DHR's established conglomerate model and BIO's focused operational profile in a volatile healthcare environment.
Introduction
Bio-Rad Laboratories (BIO) and Danaher (DHR) represent two prominent players in the life sciences and clinical diagnostics sectors. This comparison examines their business models, recent price behavior, and market positioning to assist investors and traders evaluating healthcare equipment and instrumentation exposure. The analysis draws on observable trends in relative performance, sector dynamics, and company-specific developments over recent weeks. It is particularly relevant for those monitoring life science tools, bioprocessing demand, and diagnostic market conditions in the current environment.
BIO Overview and Recent Performance
Bio-Rad Laboratories (BIO) develops and manufactures products for life science research and clinical diagnostics, including instruments, reagents, and software used in laboratories worldwide. In recent market activity, the stock has traded around the $300 level amid broader healthcare sector fluctuations. Recent weeks have seen positive influences from new product introductions, such as updated digital PCR kits for biopharma applications, alongside mentions of investor interest. These factors have contributed to a steadier sentiment compared to some peers, with the company reporting first-quarter results earlier in the year that reflected segment-specific sales patterns. Overall positioning remains tied to research spending trends and diagnostic volumes.
DHR Overview and Recent Performance
Danaher (DHR) operates as a diversified science and technology company with significant exposure to life sciences, diagnostics, and environmental solutions through its portfolio of operating companies. Recent market activity indicates the stock trading near $200-$204, reflecting declines of approximately 11% year-to-date and movement below its 50-day moving average. Influences in recent weeks include ongoing integration of prior acquisitions and sector-wide pressures on healthcare equipment demand. Earnings reports have shown modest revenue growth in core areas, yet investor focus has centered on near-term growth visibility. The company's scale provides stability but also exposes it to broader market rotations affecting large-cap healthcare names.
Trending AI Robots
Tickeron maintains a curated selection of AI trading bots designed to navigate thousands of tickers across various market conditions. While hundreds of bots are available with diverse trading styles, strategies, timeframes, and performance statistics, only those demonstrating strong suitability for prevailing environments appear in the Trending AI Robots section. Users can review ranges of historical win rates, drawdowns, and trade frequencies to assess fit. All bots differ in their approaches and the specific tickers they target. For more details on currently trending options, visit Trending AI Robots.
Head-to-Head Comparison
Bio-Rad Laboratories (BIO) maintains a specialized focus on life science research tools and diagnostics, contrasting with Danaher (DHR)'s broader conglomerate structure that includes multiple high-growth platforms. Growth drivers for BIO center on laboratory instrumentation innovation, while DHR emphasizes recurring revenue from bioprocessing and diagnostics through acquisitions. Recent momentum has favored BIO amid product launches, whereas DHR has faced greater relative pressure from valuation adjustments. Risk factors include execution on new offerings for BIO and integration challenges plus cyclical demand for DHR. Sector exposure overlaps in healthcare tools, yet BIO offers a more concentrated play and DHR provides diversified revenue streams. Market sentiment currently reflects measured caution toward larger healthcare conglomerates.
Tickeron AI Verdict
Based on observable factors such as trend consistency and recent catalysts, Tickeron’s AI would likely assign a modest probabilistic edge to Bio-Rad Laboratories (BIO) in the near term due to steadier positioning and innovation-driven updates relative to Danaher (DHR)'s broader underperformance pressures. This assessment remains conditional on continued sector dynamics and does not constitute investment guidance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a Hold and DHR is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 2 FA rating(s) are green whileDHR’s FA Score has 1 green FA rating(s).
- BIO’s FA Score: 2 green, 3 red.
- DHR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 6 TA indicator(s) are bullish while DHR’s TA Score has 4 bullish TA indicator(s).
- BIO’s TA Score: 6 bullish, 4 bearish.
- DHR’s TA Score: 4 bullish, 5 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а +3.50% price change this week, while DHR (@Medical Specialties) price change was +1.82% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.50%. For the same industry, the average monthly price growth was -7.49%, and the average quarterly price growth was -17.67%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.40%. For the same industry, the average monthly price growth was -3.39%, and the average quarterly price growth was +6.80%.
Reported Earning Dates
BIO is expected to report earnings on Aug 04, 2026.
DHR is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Medical/Nursing Services (+2.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+0.40% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BIO | DHR | BIO / DHR | |
| Capitalization | 8.63B | 137B | 6% |
| EBITDA | 440M | 7.59B | 6% |
| Gain YTD | 7.423 | -14.468 | -51% |
| P/E Ratio | 54.16 | 34.76 | 156% |
| Revenue | 2.59B | 25.1B | 10% |
| Total Cash | 1.57B | 4.35B | 36% |
| Total Debt | 1.38B | 26.6B | 5% |
BIO | DHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 73 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 90 | 79 | |
PRICE GROWTH RATING 1..100 | 12 | 52 | |
P/E GROWTH RATING 1..100 | 9 | 70 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (8) in the Medical Specialties industry is significantly better than the same rating for BIO (88). This means that DHR’s stock grew significantly faster than BIO’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BIO (100). This means that DHR’s stock grew similarly to BIO’s over the last 12 months.
DHR's SMR Rating (79) in the Medical Specialties industry is in the same range as BIO (90). This means that DHR’s stock grew similarly to BIO’s over the last 12 months.
BIO's Price Growth Rating (12) in the Medical Specialties industry is somewhat better than the same rating for DHR (52). This means that BIO’s stock grew somewhat faster than DHR’s over the last 12 months.
BIO's P/E Growth Rating (9) in the Medical Specialties industry is somewhat better than the same rating for DHR (70). This means that BIO’s stock grew somewhat faster than DHR’s over the last 12 months.
| BIO | DHR | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 68% | 3 days ago 48% |
| Stochastic ODDS (%) | 3 days ago 68% | 3 days ago 64% |
| Momentum ODDS (%) | 3 days ago 78% | 3 days ago 62% |
| MACD ODDS (%) | 3 days ago 67% | 3 days ago 65% |
| TrendWeek ODDS (%) | 3 days ago 65% | 3 days ago 55% |
| TrendMonth ODDS (%) | 3 days ago 66% | 3 days ago 54% |
| Advances ODDS (%) | 6 days ago 65% | 6 days ago 54% |
| Declines ODDS (%) | 3 days ago 69% | 3 days ago 62% |
| BollingerBands ODDS (%) | 3 days ago 87% | 3 days ago 64% |
| Aroon ODDS (%) | 3 days ago 61% | 3 days ago 65% |
Advertisement
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.